RxSight (RXST)
NASDAQ:RXST
Want to see RXST full AI Analyst Report?
RXST Stock Chart & Stats
$7.61
-$1.16(-3.26%)
At close: 4:00 PM EST
$7.61
-$1.16(-3.26%)
Day’s Range― - ―
52-Week Range$5.90 - $16.74
Previous CloseN/A
Volume110.15K
Average Volume (3M)743.31K
Market Cap
$305.37M
Enterprise Value$296.46M
Total Cash (Recent Filing)$228.13M
Total Debt (Recent Filing)$11.04M
Price to Earnings (P/E)―
Beta1.38
Next Earnings
May 06, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding41,266,335
10 Day Avg. Volume746,305
30 Day Avg. Volume743,307
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)1.56
Price to Sales (P/S)3.19
P/FCF Ratio-22.18
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue2.20
Enterprise Value/Gross Profit2.88
Enterprise Value/Ebitda-7.48
Forecast
1Y Price Target
$10.33Price Target Upside35.79% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)-1.32
Revenue Forecast (FY)$129.19M
Bulls Say, Bears Say
Bulls Say
Installed Base GrowthMeaningful expansion of the installed base increases the addressable market and provides a foundation for recurring procedure volume and follow-on revenue as adoption scales.
Management ExpertiseAppointment of an experienced finance executive as CFO brings senior medical device finance expertise, which can strengthen financial oversight and investor confidence during the company’s operational transition.
Product DifferentiationAdjustable intraocular lens that can be modified after implantation allows surgeons to fine-tune patient vision outcomes, creating a differentiated product that supports premium positioning and continued adoption.
Bears Say
Adoption Hurdles For SurgeonsAdditional post-operative visits and increased procedural work required for the adjustable lens make it harder for surgeon offices to adopt the product, slowing sales ramp among newly trained surgeons.
Cost And Margin PressureLower production volumes are creating higher per-unit manufacturing costs and expected gross margin pressure, which could constrain profitability until volumes recover.
Macroeconomic And Pricing RiskMacroeconomic headwinds may reduce uptake of premium products and weaken pricing power, limiting revenue growth potential in more price-sensitive segments.
RxSight News
RXST FAQ
What was RxSight’s price range in the past 12 months?
RxSight lowest stock price was $5.90 and its highest was $16.74 in the past 12 months.
What is RxSight’s market cap?
RxSight’s market cap is $305.37M.
When is RxSight’s upcoming earnings report date?
RxSight’s upcoming earnings report date is May 06, 2026 which is in 2 days.
How were RxSight’s earnings last quarter?
RxSight released its earnings results on Feb 25, 2026. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.335 by $0.115.
Is RxSight overvalued?
According to Wall Street analysts RxSight’s price is currently Undervalued.
Does RxSight pay dividends?
RxSight does not currently pay dividends.
What is RxSight’s EPS estimate?
RxSight’s EPS estimate is -0.3.
How many shares outstanding does RxSight have?
RxSight has 41,266,335 shares outstanding.
What happened to RxSight’s price movement after its last earnings report?
RxSight reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.335. Following the earnings report the stock price went down -10.102%.
Which hedge fund is a major shareholder of RxSight?
Currently, no hedge funds are holding shares in RXST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RxSight Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$10.33 (35.79% Upside)
$10.33 (35.79% Upside)
Blogger Sentiment
Bullish
RXST Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 577.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.26%
12-Months-Change
Fundamentals
Return on Equity
-14.05%
Trailing 12-Months
Asset Growth
-2.20%
Trailing 12-Months
Company Description
RxSight
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
RXST Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: notable operational and clinical strengths (strong LAL margins, improving sequential LAL volumes, compelling clinical evidence, a growing installed base and a robust cash position) but also material near-term headwinds (large LDD revenue decline, a wider GAAP loss, manufacturing-driven margin pressure and conservative 2026 guidance). Management emphasized early signs of commercial improvement and a measured plan to drive utilization and international expansion, while remaining prudent in 2026 assumptions.View all RXST earnings summariesRXST Stock 12 Month Forecast
Average Price Target
$10.33
▲(35.79% Upside)
Technical Analysis
Delcath Systems
―
Senseonics Holdings
―
Butterfly Network
―
NeuroPace
―
Ceribell, Inc.
―
Ownership Overview
5.58% Insiders
13.76% Mutual Funds
1.15% Other Institutional Investors
65.45% Public Companies and
Individual Investors